⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Ravulizumab Use for Acetylcholine Receptor-positive Generalized Myasthenia Gravis in Clinical Practice (P4-11.007)

Nakul Katyal Raghav Govindarajan Neelam Goyal Srikanth Muppidi Suraj Muley

View Full Paper

Ask AI

Bookmark

Share

Abstract

To describe the early experience of ravulizumab use in acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ve gMG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Katyal et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677ce4 https://doi.org/10.1212/wnl.0000000000204526

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice2024 · 10 citations
2Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: Final Results from the Phase 3 CHAMPION MG Open-label Extension (S15.010)2024 · 5 citations
3Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the <scp>CHAMPION MG</scp> study2024 · 12 citations
4Patient Satisfaction With Ravulizumab Treatment for Generalized Myasthenia Gravis (gMG) in the United States (US) (P11-9.003)Original Research · 2026
5Evaluating the Real‐World Safety of Ravulizumab in Generalized Myasthenia Gravis: Insights From a Detailed Analysis of FAERS DataOriginal Research · 2026